Acute Effects of Single-Dose Olanzapine on Metabolic, Endocrine, and Inflammatory Markers in Healthy Controls
| Autor: | Tom Wolever, Margaret Hahn, Leigh Clarke, Valerie Powell, Adria Giacca, Celine Teo, Sylvia Gomes, Roger S. McIntyre, Paul Fletcher, Araba Chintoh, Gary Remington, Tony Cohn, Tamara Arenovich |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Blood Glucose Male Acute effects Olanzapine medicine.medical_specialty Hydrocortisone Type 2 diabetes Fatty Acids Nonesterified Benzodiazepines Text mining Adipokines Double-Blind Method Internal medicine medicine Humans Insulin Glucose homeostasis Endocrine system Pharmacology (medical) Cross-Over Studies business.industry Direct effects Glucose Tolerance Test Lipid Metabolism medicine.disease Prolactin Psychiatry and Mental health Increasing risk Endocrinology Female Insulin Resistance business Antipsychotic Agents medicine.drug |
| Zdroj: | Journal of Clinical Psychopharmacology. 33:740-746 |
| ISSN: | 0271-0749 |
| Popis: | Atypical antipsychotics may "directly" influence glucose homeostasis, increasing risk of type 2 diabetes independently of changes in adiposity. Animal models suggest direct effects after even a single dose of certain atypical antipsychotics on glucose dysregulation. Here, we investigated effects of a single-dose olanzapine (OLA) on glucose metabolism in healthy volunteers, thereby minimizing confounding effects of the illness of schizophrenia and adiposity. In a randomized double-blind crossover design, 15 subjects were administered 10 mg of OLA or placebo at 7:00 A.M. on separate study dates. A frequently sampled intravenous glucose tolerance test was initiated 4.25 hours later to assess changes in glucose homeostasis, including an index of insulin sensitivity, disposition index, glucose effectiveness, and acute insulin response to glucose. We also examined effects on cortisol, prolactin, fasting free fatty acids (FFAs), insulin-mediated suppression of FFAs, and adipocytokines (leptin, adiponectin, C-reactive protein, interleukin 6, and tumor necrosis factor α). Complete data for both visits were analyzed for 12 subjects. Olanzapine treatment significantly decreased glucose effectiveness (P = 0.041) and raised fasting glucose over 4.25 hours (P = 0.03) as compared to placebo. Olanzapine was associated with lower serum cortisol (P = 0.003), lower fasting FFA (P = 0.042), and increased prolactin levels (P0.0001). We therefore suggest that a single dose of OLA may invoke early changes in some parameters of glucose and lipid metabolism, as well as endocrine indices. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|